||Antimutagenicity Profiles of Some Natural Substances.
Brockman, H. E. ;
Stack, H. F. ;
Waters, M. D. ;
||Health Effects Research Lab., Research Triangle Park, NC. ;Illinois State Univ., Normal. Dept. of Biological Sciences. ;Environmental Health Research and Testing, Inc., Research Triangle Park, NC.
Chromosome aberrations ;
Salmonella typhimurium ;
Sister chromatid exchange ;
In vivo analysis ;
In vitro analysis ;
||Some EPA libraries have a fiche copy filed under the call number shown.
Selected antimutagenicity listings and profiles have been prepared from the literature on the antimutagenicity of retinoids and the carotenoid Beta-carotene. The antimutagenicity profiles show: (1) a single antimutagen (e.g., retinol) tested in combination with various mutagens or (2) antimutagens tested against a single mutagen (e.g., aflatoxin B(1)). Data are presented in the profiles showing a dose range for a given antimutagen and a single dose for the corresponding mutagen; inhibition as well as enhancement of mutagenic activity is indicated. Information was found in the literature on the testing of selected combinations of 16 retinoids and carotenoids vs. 33 mutagens. Of 528 possible antimutagen-mutagen combinations, only 82 (16%) have been evaluated. The most completely evaluated retinoids are retinol (28 mutagens), retinoic acid and retinol acetate (7 mutagens each), and retinal and retinol palmitate (6 mutagens each). Beta-Carotene is the most frequently tested carotenoid (15 mutagens). Of the remaining retinoids and carotenoids, 8 were evaluated in combination with a single mutagen and the other 2 were tested against only 2 or 3 mutagens. Most of the data on antimutagenicity in vitro are available for S. typhimurium strains TA98 and TA100. Substantial data also are available for sister-chromatid exchanges in vitro and chromosome aberrations in vitro and in vivo. The report emphasizes the metabolic as well as the antimutagenic effects of retinoids in vitro and in vivo. (Copyright (c) 1992 Elsevier Science Publishers B.V.)